These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 19783811)

  • 1. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
    Cipriani S; Mencarelli A; Palladino G; Fiorucci S
    J Lipid Res; 2010 Apr; 51(4):771-84. PubMed ID: 19783811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
    Mencarelli A; Cipriani S; Renga B; D'Amore C; Palladino G; Distrutti E; Baldelli F; Fiorucci S
    Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):94-101. PubMed ID: 21924881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance.
    Ma Y; Huang Y; Yan L; Gao M; Liu D
    Pharm Res; 2013 May; 30(5):1447-57. PubMed ID: 23371517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
    Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
    Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiatherosclerotic effect of farnesoid X receptor.
    Mencarelli A; Renga B; Distrutti E; Fiorucci S
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
    Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
    Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
    Liu LF; Purushotham A; Wendel AA; Belury MA
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model.
    Zhang HM; Wang X; Wu ZH; Liu HL; Chen W; Zhang ZZ; Chen D; Zeng TS
    Mol Med Rep; 2016 Mar; 13(3):2135-42. PubMed ID: 26782298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
    Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A
    Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
    Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
    Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
    Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
    Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats.
    Tovar AR; Torre-Villalvazo I; Ochoa M; Elías AL; Ortíz V; Aguilar-Salinas CA; Torres N
    J Lipid Res; 2005 Sep; 46(9):1823-32. PubMed ID: 15995177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
    Fiorucci S; Rizzo G; Antonelli E; Renga B; Mencarelli A; Riccardi L; Morelli A; Pruzanski M; Pellicciari R
    J Pharmacol Exp Ther; 2005 Oct; 315(1):58-68. PubMed ID: 15980055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.
    Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X
    Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
    Gai Z; Gui T; Hiller C; Kullak-Ublick GA
    J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.
    Kuhlmann J; Neumann-Haefelin C; Belz U; Kalisch J; Juretschke HP; Stein M; Kleinschmidt E; Kramer W; Herling AW
    Diabetes; 2003 Jan; 52(1):138-44. PubMed ID: 12502504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.
    Chakrabarti R; Vikramadithyan RK; Kumar MP; Kumar SK; Mamidi NV; Misra P; Suresh J; Hiriyan J; Rao CS; Rajagopalan R
    Diabetes Obes Metab; 2002 Sep; 4(5):319-28. PubMed ID: 12190995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesoid X Receptor Expression Reduced in Obese Rat Model With Insulin Resistance.
    Pang S; Yu L; Lu Y; Jiang Q; Hou L; Shi R; Ding L; Wang C; Duan G
    Am J Med Sci; 2015 Dec; 350(6):467-70. PubMed ID: 26488943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.